Breast Cancer Clinical Trial

A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer

Summary

The purpose of this study is to see whether 18F-FDHT PET/MRI scans are an effective way of identifying AR-positive breast cancer.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Age ≥ 18 years
ECOG performance score of 0-2
Signed informed consent

Histologically confirmed AR+ breast cancer

All participants under consideration for enrollment will have their tumor specimen tested centrally at MSK; nuclear AR staining ≥ 1% will be considered positive.
Progressive metastatic breast cancer manifested as increase in evaluable disease OR the appearance of new sites of disease since the date of the last imaging study performed and under consideration for AR-targeted therapy
Planning to undergo treatment with agents targeting the antiandrogen signaling pathway on a clinical trial

Exclusion Criteria:

Life expectancy < 3 months
Pregnancy or lactation

Participants who cannot undergo scanning because of

weight limits
devices or implants that are not MRI safe
allergies to contrast materials
CNS only disease on recent imaging

Study is for people with:

Breast Cancer

Phase:

Early Phase 1

Study ID:

NCT06145399

Recruitment Status:

Withdrawn

Sponsor:

Memorial Sloan Kettering Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States More Info
Maxine Jochelson, MD
Contact
646-888-4507
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Early Phase 1

Study ID:

NCT06145399

Recruitment Status:

Withdrawn

Sponsor:


Memorial Sloan Kettering Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.